These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The occurrence of malignant carcinoid syndrome in patients with carcinoid tumors. Kinova S; Duris I; Bulas J; Murin J; Kovacova E; Stenova E; Jurkovicova I; Makaiova I Bratisl Lek Listy; 2002; 103(2):45-9. PubMed ID: 12061020 [TBL] [Abstract][Full Text] [Related]
5. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194 [TBL] [Abstract][Full Text] [Related]
6. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI; Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775 [TBL] [Abstract][Full Text] [Related]
7. [Occurrence of carcinoid syndrome in patients with carcinoid tumors]. Kinová S; Kovácová E; Bulas J; Murín J; Belovicová M; Jurkovicová I; Duris I Vnitr Lek; 2004 Feb; 50(2):126-33. PubMed ID: 15077587 [TBL] [Abstract][Full Text] [Related]
8. An update of lanreotide acetate for treatment of adults with carcinoid syndrome. Guadalupe E; Deshpande HA; Stein SM Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440 [TBL] [Abstract][Full Text] [Related]
9. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606 [TBL] [Abstract][Full Text] [Related]
10. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645 [TBL] [Abstract][Full Text] [Related]
11. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. Rohaizak M; Farndon JR ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913 [TBL] [Abstract][Full Text] [Related]
12. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Tomassetti P; Migliori M; Gullo L Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927 [TBL] [Abstract][Full Text] [Related]
13. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. Drange MR; Melmed S J Clin Endocrinol Metab; 1998 Sep; 83(9):3104-9. PubMed ID: 9745411 [TBL] [Abstract][Full Text] [Related]
14. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874 [TBL] [Abstract][Full Text] [Related]
15. Carcinoid of the pancreas. Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097 [TBL] [Abstract][Full Text] [Related]
16. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY. Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI; Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049 [TBL] [Abstract][Full Text] [Related]
18. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues. Gut P; Ruchała M Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367 [TBL] [Abstract][Full Text] [Related]
20. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G Oncology; 2001; 60(2):141-5. PubMed ID: 11244329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]